Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905065 | 0.87 | AKR1C3 (0.49) | MAPK14MAPK13MAPK12MAPK11AKR1C3 | |
| SCHEMBL7646956 | 0.86 | AKR1C3 (0.46) | MAPK14MAPK13MAPK12MAPK11AKR1C3 | |
| SCHEMBL6396818 | 0.85 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL7198684 | 0.84 | AKR1C3 (0.53) | MAPK14MAPK13MAPK12MAPK11AKR1C3 | |
| SCHEMBL6910336 | 0.84 | AKR1C3 (0.43) | MAPK14MAPK13MAPK12MAPK11AKR1C3 | |
| SCHEMBL6824663 | 0.82 | MAPK13 (0.48) | MAPK14MAPK13MAPK12MAPK11AKR1C3 | |
| SCHEMBL6817857 | 0.81 | HTT (0.44) | MAPK14MAPK13MAPK12MAPK11AKR1C3 | |
| SCHEMBL6817865 | 0.81 | HTT (0.44) | MAPK14MAPK13MAPK12MAPK11AKR1C3 | |
| SCHEMBL6399972 | 0.79 | AKR1C3 (0.40) | MAPK14MAPK13MAPK12MAPK11AKR1C3 | |
| SCHEMBL6906583 | 0.79 | AKR1C3 (0.42) | MAPK14MAPK13MAPK12MAPK11AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202954-B1 | NOVEL AMINOBENZOPHENONES | LEO PHARMA AS (DK) | 2003-10-01 | — | — | EP | claimed |
| US-6624199-B1 | Prophylaxis and treatment of acne and acne related skin diseases with aminobenzophenones, and novel compounds effective in the treatment, as well as pharmaceutical preparations containing these compounds and dosage units | LEO PHARMACEUTICALS PRODUCTS LTD. A/S (DK) | 2003-09-23 | — | — | US | claimed |
| US-20020165286-A1 | Dermal anti-inflammatory composition | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-11-07 | — | — | US | claimed |
| WO-2002045752-A2 | DERMAL ANTI-INFLAMMATORY COMPOSITION | LEO PHARMA A/S (DK) | 2002-06-13 | — | — | WO | claimed |
| EP-1202954-A1 | NOVEL AMINOBENZOPHENONES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005744-A1 | NOVEL AMINOBENZOPHENONES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | claimed |
| US-6897236-B1 | Aminobenzophenones as inhibitors of IL-1β and TNF-α | LEO PHARMACEUTICAL PRODUCTS, LTD. (DK) | 2005-05-24 | — | — | US | disclosed |
| EP-1210325-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-10-06 | — | — | EP | disclosed |
| EP-1202959-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1-BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| EP-1210320-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| EP-1202957-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| US-6750253-B1 | INHIBITION OR DOWN REGULATION OF THE CYTOKINES IS POSSIBLY DUE TO AN INHIBITION OF MAP KINASES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2004-06-15 | — | — | US | disclosed |
| EP-1202954-B1 | NOVEL AMINOBENZOPHENONES | LEO PHARMA AS (DK) | 2003-10-01 | — | — | EP | disclosed |
| EP-1202954-A1 | NOVEL AMINOBENZOPHENONES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | disclosed |
| EP-1202957-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005749-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005745-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005751-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005746-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005744-A1 | NOVEL AMINOBENZOPHENONES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165286-A1 | Dermal anti-inflammatory composition | CUTA, IL1B, LRBA | MAPK14 644/4885MAPK13 1521/4885MAPK12 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.